Health Catalyst Inc. (HCAT)
Down 21.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Health Catalyst (HCAT) Is a Great 'Buy the Bottom' Stock Now
Health Catalyst (HCAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Health Catalyst, Inc. (HCAT) Q3 2025 Earnings Call Transcript
Health Catalyst, Inc. ( HCAT ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Matt Hopper Daniel Burton - CEO & Director Benjamin Albert - President & COO Jason Alger - Chief Financial Officer Conference Call Participants Jared Haase - William Blair & Company L.L.C., Research Division Jessica Tassan - Piper Sandler & Co., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Richard Close - Canaccord Genuity Corp., Research Division Daniel Grosslight - Citigroup Inc., Research Division David Larsen - BTIG, LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Jeffrey Garro - Stephens Inc., Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Welcome to the Health Catalyst Third Quarter 2025 Earnings Conference Call.
Health Catalyst (HCAT) Q3 Earnings and Revenues Top Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.07 per share a year ago.
Health Catalyst (HCAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Health Catalyst (HCAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Impax Small Cap Fund Q3 2025 Contributors And Detractors
Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asset Management & Custody Banks) saw another quarter of better-than-expected flows, driving earnings upside relative to expectations. SI-Bone (SIBN) (Health Care, Health Care Equipment) was weaker despite reporting a marginal beat on revenue and expectations of improved profitability.
Health Catalyst, Inc. (HCAT) Q2 2025 Earnings Call Transcript
Health Catalyst, Inc. (NASDAQ:HCAT ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Daniel LeSueur - Chief Operating Officer Daniel D. Burton - CEO & Director Jack Knight - Corporate Participant Jason Alger - Chief Financial Officer Conference Call Participants Daniel R.
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago.
Health Catalyst (HCAT) Upgraded to Buy: Here's Why
Health Catalyst (HCAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Health Catalyst: Ignite Platform Is A Growth Catalyst
I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT's large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management's FY25 guidance and signaling a potential inflection point for the business.
